Moderna stock tumbled after the Senate Finance Committee voted to send RFK Jr.'s nomination for the HHS secretary to the full ...

Approved by the FDA in May 2024, Moderna’s mRNA shot, mRESVIA, only generated $10 million in sales during the third quarter, its RSV season debut. Besides the impact of a narrowed CDC policy ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

20, 2023, in Cypress, Texas. Weak adoption of Moderna’s respiratory syncytial virus (RSV) vaccine has exacerbated financial pressures, with the product... Pharmacist Kim Nguyen administers a ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Moderna's RSV vaccine earned approval last May, but sales haven't gotten off the ground yet. The biotech company expects to lose money again in 2025, but operating expenses are declining.

amid its advantages over some of the other RSV vaccines. Moderna’s RSV shot can be stored frozen and comes in a syringe, implying faster and easy administration. It also has no reported Guillain ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business." MRNA Stock Is in a ...

(AP Photo/Eugene Hoshiko, File)(Eugene Hoshiko / AP) Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by slow adoption of its respiratory syncytial virus (RSV) shot and weak ...